Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan速 \[Rituxan速 as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory follicular NHL\], has in this patient population.
Non-Hodgkin's Lymphoma
DRUG: IDEC-114
To characterize the safety profile and to define the dose of galiximab to be used for the Phase II portion of the study, March 2010
To evaluate PK, March 2010|To evaluate efficacy, March 2010|To monitor for the presence of human anti galiximab antibody and human antichimeric antibody formation, March 2010
To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan速 \[Rituxan速 as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory follicular NHL\], has in this patient population.